Form 4: C4 Therapeutics Director Kenneth Anderson Reports Changes in Beneficial Ownership

Director Kenneth Anderson reports acquisition of shares in C4 Therapeutics through non-employee director compensation and disposition of shares, with adjustments to beneficial ownership.

Summary

• On April 1, 2024, Kenneth Anderson, a director of C4 Therapeutics, reported changes in his beneficial ownership of the company's common stock.
• Anderson acquired 1,389 shares at a price of $8.10 per share as part of the Issuer's Non-Employee Director Compensation Policy, where he elected to receive shares in lieu of cash compensation.
• Following the transaction, Anderson directly owns 112,351 shares.
• He also has indirect ownership through his spouse (47,316 shares) and grantor retained annuity trusts (61,265 shares each for Kenneth and Cynthia Anderson's 2016 trusts), as well as irrevocable trusts (16,939 shares each for Kenneth and Cynthia Anderson's 2015 trusts).
• Anderson disclaims beneficial ownership of shares held by the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing. The director's acquisition of shares could be seen as slightly positive, but it's part of a compensation plan.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the transactions of company insiders.

Key Dates